Meningitis vaccine boosts immune response

Thursday, May 08, 2008; Posted: 12:24 AM

7 Stocks You Need To Know For Tomorrow -- Free Newsletter

HONOLULU, May 8, 2008 (UPI via COMTEX) -- NVS | news | PowerRating | PR Charts -- Swiss-based Novartis says clinical trials show its new Menveo vaccine is effective in preventing four types of meningitis.

The drug, which has been developed for use from early infancy through adulthood, is in Phase III clinical trials, the company said in a news release.

The data was presented this week at the Pediatric Academic Societies' annual meeting in Honolulu.

A trial involving more than 2,100 11- to 18-year-olds showed Menveo helped trigger a strong immune response in a greater percentage of adolescents than the Sanofi-Aventis vaccine Menactra. Novartis said it plans to file for approval in the United States and Europe this year, The Wall Street Journal reported.

Meningitis kills 10 percent to 14 percent of the 1,400 to 2,800 U.S. patients diagnosed with the bacterial disease each year, the newspaper said.

www.upi.com

For full details on Novartis Ag Ads (NVS) click here. Novartis Ag Ads (NVS) has Short Term PowerRatings of 5. Details on Novartis Ag Ads (NVS) Short Term PowerRatings is available at This Link.

Morning Coffee with TradingMarkets -- Free Newsletter

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.